We also show that Dnmt1–Trt2/Ctcf-mediated reversible modulation of Cmip methylation regulates the Gbp2–Pparγ–Cd36 signaling pathway, indicating the potential of Cmip as a novel therapeutic target for NAFLD. Here, DNMT1 is linked to metabolic dysfunction-associated steatotic liver disease.